Status:
COMPLETED
Empagliflozin and Sympathetic Nerve Traffic
Lead Sponsor:
Profil Institut für Stoffwechselforschung GmbH
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
50-80 years
Phase:
PHASE4
Brief Summary
In this study the effects of the Inhibition of the Sodium-Glucose Linked Transporter 2 in the kidney with empagliflozin compared to hydrochlorothiazide on blood pressure and on central sympathic nervo...
Detailed Description
The drug empagliflozin is a selective oral inhibitor of the sodium-glucose co-transporter 2 (SGLT-2) in the kidney.On the market empagliflozin is approved for the treatment of type 2 Diabetes. The mec...
Eligibility Criteria
Inclusion
- women and men \>= 50 and \<= 80 years of age
- type 2 diabetes mellitus for \>=2 years
- only metformin monotherapy is allowed; metformin dose must have been stable for \>=12 weeks
Exclusion
- previous empagliflozin treatment within the last 3 months
- heart failure NYHA II - IV
- subjects who have received any investigational medicinal product or have used any investigational medical device within 30 days prior to the screening visit, or who are actively participating in any investigational medicinal product or medical device trial, or who are scheduled for any such trial during the course of the trial.
Key Trial Info
Start Date :
December 8 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 20 2020
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT03254849
Start Date
December 8 2017
End Date
April 20 2020
Last Update
July 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Profil Institut für Stoffwechselforschung GmbH
Neuss, North Rhine-Westphalia, Germany, 41460